CANTOR FITZGERALD REITERATES PureCycle STOCK RATING AT OVERWEIGHT

Cantor Fitzgerald reiterated its Overweight rating on PureCycle Technologies (PCT) with a $12 price target, citing the company's patented technology, first-mover advantage, and scalability potential. The firm is encouraged by PureCycle's first revenue report and Q1 production of 4.3 million pounds of resin at its Ironton facility, while also noting approximately 14 million pounds of inventory. Despite a current ratio indicating potential liquidity challenges and negative EBITDA, Cantor Fitzgerald views PureCycle's expansion into a new Georgia facility as a meaningful catalyst, expecting it to become operational in fiscal year 2027.

Analysis

Cantor Fitzgerald has reiterated an Overweight rating and a $12.00 price target on PureCycle Technologies (NASDAQ:PCT), which currently trades at $11.01 and has demonstrated significant momentum with an 86% return over the past year. The firm's optimism is rooted in PureCycle's patented technology licensed from Procter & Gamble, its first-mover advantage in a substantial total addressable market, and its inherent scalability. Operationally, PureCycle has achieved key milestones, reporting its first-ever revenue and producing 4.3 million pounds of resin in Q1 at its Ironton facility, which also saw improved operational efficiency with 90% on-stream time in April. The company currently holds approximately 14 million pounds of inventory and is actively engaged with customers, conducting over 30 trials (24 at the industrial stage), with three having already converted to purchase orders. Future growth is anticipated from the expansion into a new Georgia facility, projected to be operational in fiscal year 2027, and the Ironton facility is targeting breakeven by the third quarter of 2025. Despite these positive developments, PureCycle remains unprofitable, with a negative EBITDA of $114.7 million over the last twelve months, and InvestingPro data indicates potential liquidity challenges with a current ratio of 0.55. The company recently raised nearly $55 million through private stock placement and revenue bonds, ending the quarter with $37.5 million in cash, including $22.5 million unrestricted. Cantor Fitzgerald recently adjusted its price target downwards from $14 to $12, while maintaining its Overweight rating, reflecting continued confidence tempered by execution timelines.

Key Decisions for Investors

• Investors should weigh PureCycle's significant long-term growth potential, underpinned by its proprietary technology, strong initial production figures (4.3 million pounds in Q1), and extensive customer trials, against the inherent risks associated with its current unprofitability (LTM EBITDA -$114.7M) and the recent downward price target revision by Cantor Fitzgerald.
• Careful monitoring of operational execution is crucial, specifically the Ironton facility's progress towards its Q3 2025 breakeven target, the conversion rate of its 30+ customer trials into sustained sales volumes, and developments concerning the new Georgia facility planned for FY2027.
• Assess the company's liquidity position and cash burn rate carefully, given the current ratio of 0.55, and be mindful of potential future financing needs to support its expansion plans, despite the recent $55 million capital raise.